What is SLU-PP-332?

What is SLU-PP-332?

SLU-PP-332 is a small-molecule synthetic agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), developed and used as an exercise-mimetic chemical probe. It is a pan-ERR agonist, meaning it activates all three ERR subtypes, and it has been characterised analytically by liquid chromatography–high resolution tandem mass spectrometry (LC-HRMS/MS) alongside the related compound SLU-PP-915 [1]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for SLU-PP-332, so none is stated here. The compound is also referred to in the literature as an ERRα/β/γ agonist and as an exercise mimetic [4].

The pathway at the centre of this work is estrogen-related receptor signalling: ERRs are orphan nuclear receptors that act as master regulators of mitochondrial metabolism and exercise-responsive transcription [2].

Research Studies

SLU-PP-332 and in vitro metabolic transformation in human liver S9 fractions

SLU-PP-332 and SLU-PP-915 were characterised by LC-HRMS/MS, and the in vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions [1]. The stated rationale for that work was that ERR agonists are being investigated as exercise mimetics because of their ability to trigger human physiological processes similar to those initiated by physical activity, which prompted consideration of these compounds as drugs potentially relevant to sports drug testing programmes [1]. The study is an analytical and in vitro metabolism study; it does not report an in vivo efficacy endpoint.

SLU-PP-332 and structure–activity relationships across the ERR scaffold

The first comprehensive structure–activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling and further characterisation [2]. That work was framed around the observation that only a limited number of synthetic ERR agonists with suitable potency and drug-like properties had been reported, and that the structural features governing the potency, efficacy, selectivity and drug-like properties of SLU-PP-332 had not been systematically elucidated [2]. The findings are therefore mechanistic and structure-oriented rather than clinical.

SLU-PP-332 and ERR activation in myoblasts from inactive women

A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women, assessing the metabolic and expression changes associated with ERR activation [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) on the basis of self-reported physical activity [3]. The introduction to that study notes that ERRs have been suggested as a potential therapeutic target to counteract muscle decline associated with ageing or inactivity, being known to regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [3]. This is an ex vivo human myoblast study, not a clinical trial of the compound in a treated population.

SLU-PP-332 and doping-control metabolite identification

Separate work analysed and identified in vitro metabolites of SLU-PP-332 for doping-control purposes, in the context that exercise mimetics mimic physical activity and that the World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sport [4]. That paper describes SLU-PP-332 as a small synthetic ERRα/β/γ agonist [4]. It is an analytical identification study and does not report physiological outcomes.

SLU-PP-332 and pharmacological ERR activation as an exercise mimetic

A review examined pharmacological activation of ERRα/β/γ as an exercise mimetic and its potential therapeutic applications, on the premise that physical inactivity contributes to the development of chronic diseases and that activation of the orphan nuclear receptors ERRα/β/γ has emerged as a molecular strategy to mimic exercise-induced benefits [5]. The stated aim was to systematically review the current evidence on the physiological, molecular and clinical dimensions of that strategy [5]. As a review, it synthesises prior work rather than generating new experimental data.

SLU-PP-915 and aerobic exercise capacity

The related orally active ERR agonist SLU-PP-915 was reported to enhance aerobic exercise capacity [6]. That work describes ERRα, ERRβ and ERRγ as orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle, and states that ERRs are essential for skeletal muscle adaptation to aerobic exercise and represent promising targets in that setting [6]. This finding concerns SLU-PP-915, not SLU-PP-332, and should not be read across between the two compounds.

SLU-PP-332 and metabolic syndrome in preclinical models

A synthetic ERR agonist was reported to alleviate metabolic syndrome, in work that describes physical exercise as inducing physiological adaptations and being effective at reducing the risk of premature death from all causes, and that frames pharmacological exercise mimetics as potentially effective in the treatment of a range of diseases including obesity and metabolic syndrome [7]. That paper states that SLU-PP-332 had previously been described in the course of that development programme [7]. The findings are preclinical.

SLU-PP-332 and comparison with SLU-PP-915

Two ERR agonists appear repeatedly across the evidence base, and the table below sets out what each source states about them. It is a summary of reported scope, not a head-to-head potency comparison; the evidence block does not provide comparative potency values.

SLU-PP-332 and the limits of the current evidence

Across the sources supplied here, the work on SLU-PP-332 falls into three categories: analytical and in vitro metabolism studies [1][4], structure–activity and mechanism studies [2], and ex vivo human cell work [3]. The review and the metabolic-syndrome paper address ERR agonism as a strategy and a preclinical finding respectively [5][7], and the aerobic-capacity finding concerns SLU-PP-915 rather than SLU-PP-332 [6]. No source in this evidence block reports a controlled clinical trial of SLU-PP-332 in a treated human population, and no source reports a human dose. Statements about ERR biology in this page describe the receptor family and the models used, not outcomes established in humans.

If you are reading this for personal health reasons

SLU-PP-332 is sold by this catalogue as a laboratory research material only, and we do not provide dosing information or medical guidance of any kind. Nothing on this page is a recommendation to use this compound in a person. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — https://europepmc.org/article/PMC/PMC12835572
• [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — https://europepmc.org/article/PMC/PMC13112601
• [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study — https://europepmc.org/article/PMC/PMC12277287
• [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — https://pubmed.ncbi.nlm.nih.gov/41688415/
• [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications] — https://pubmed.ncbi.nlm.nih.gov/42024694/
• [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity — https://pubmed.ncbi.nlm.nih.gov/41421047/
• [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome — https://europepmc.org/article/PMC/PMC10801787